|Articles|February 24, 2016

What Lies Ahead for 2016: The DIA's Annual Report

Author(s)DIA

February 24, 2016.

What Lies Ahead 2016

DIA’s exclusive annual survey catalogs, ranks, and describes trends to watch in biopharmaceutical, device, and related research, development, and regulation, from expert global and regional perspectives, in the year ahead.

Read the article here.

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

What Lies Ahead for 2016: The DIA's Annual Report

Related Content

Chai Discovery Enters License Agreement with Pfizer to Accelerate Drug Discovery with AI

Alnylam Enters $2 Billion Strategic AI Collaboration with Inceptive

Modernizing Market Access and Patient Support Services: Q&A with Cam Olig

The Evolving Biopharma Regulatory Landscape: Q&A with Harpreet Singh, MD

How Do You Think Ai Can Improve FDA's Internal Process?

Trending on PharmExec

Alnylam Enters $2 Billion Strategic AI Collaboration with Inceptive

U.S. Supreme Court Unanimously Votes in Favor of Hikma in Case Against Amarin: Report

Chai Discovery Enters License Agreement with Pfizer to Accelerate Drug Discovery with AI

Navigating PBM Pitfalls: Protecting Revenue in a Complex Rebate Landscape

Pharmaceutical Executive Daily: New FDA Draft Guidance Targets Gene Therapy Submission Burden